Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” ...

Healthcare providers are making cybersecurity progress, but serious vulnerabilities remain — especially when it comes to AI governance, third-party risk, and limited budgets. Fortified Health ...

Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has ...

Hengrui’s peptide drug, HRS9531, is engineered to bind to and activate the GLP-1 and GIP receptors — the same two targets hit by blockbuster Eli Lilly’s chronic weight management drug ...